Additional Poster News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Feb 25, 2021
GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported updated safety, efficacy and long-term use results of
UPLIZNA
® (inebilizumab-cdon), including interim data from the open-label extension period (OLP) of the pivotal N-MOmentum trial in patients with neuromyelitis optica spectrum disorder (NMOSD). Data from four scientific abstracts were selected for presentations during the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum, which is being held virtually from February 25-27, 2021.
Among the highlights in patients treated with ....

United States , Mark Tullman , Viela Bio , Amy Bonanno , Jorn Drappa , Bruce Cree , Benjamin Greenberg , Exchange Commission , American Committee For Treatment , Research In Multiple Sclerosis , Adjudication Committee , American Committee , Multiple Sclerosis , Chief Medical Officer , Neuromyelitis Optica Spectrum Disorder , Long Term Open Label Efficacy , Clinical Neurology , California San Francisco Weill Institute , Risk During , Previous Rituximab , Michael Levy , Additional Poster , Infusion Reactions , Infusion Times , Neuromyelitis Optica Spectrum Disorders , Progressive Multifocal Leukoencephalopathy ,